Jason Kantor

In a report published Friday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating and $79.00 price target on Kite Pharma Inc. (NASDAQ: KITE). In the report, Credit Suisse noted, "KITE ended 2014 with $367M cash and cash equivalents and expects approximately $300M at year-end...

In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated a Neutral rating and $5.00 price target on XOMA Corp. (NASDAQ: NASDAQ: XOMA). In the report, Credit Suisse noted, "We anticipate that the final event in the EYEGUARD B trial will occur soon, and this will trigger an...

In a report published Friday, Credit Suisse analyst Jason Kantor reiterated a Neutral rating on Pharmacyclics, Inc. (NASDAQ: PCYC), and raised the price target from $233.00 to $261.00. In the report, Credit Suisse noted, "We are increasing our target price to $261, the agreed purchase price from...

Credit Suisse on Thursday issued a report on Pharmacyclics, Inc. (NASDAQ: PCYC) a day after the company soared 17 percent following acquisition rumors. Credit Suisse downgraded Pharmacyclics from Outperform to Neutral and raised its price target from $163 to $233. A report  issued by...

In a report published Tuesday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating on Kite Pharma Inc (NASDAQ: KITE), and raised the price target from $71.00 to $79.00. In the report, Credit Suisse noted, “The AMGN deal is a significant positive for KITE, which (1) gains access to...

In a report published Friday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating on Kite Pharma (NASDAQ: KITE), and raised the price target from $34.00 to $71.00. In the report, Credit Suisse noted, “The strong showing of CAR-T therapies at the recent ASH meeting and the recent...

In a report published Thursday, Credit Suisse analyst Jason Kantor downgraded the rating on Ariad Pharmaceuticals (NASDAQ: ARIA) from Neutral to Underperform, and lowered the price target from $8.00 to $6.00. In the report, Credit Suisse noted, “We believe that Iclusig will likely remain the last...

Credit Suisse upgraded The Medicines Company (NASDAQ: MDCO) Thursday from Neutral to Outperform and raised its price target from $27 to $33. Analysts led by Jason Kantor noted that “investor sentiment is currently very bearish and several factors could significantly improve the outlook...

In a report published Thursday, Credit Suisse analyst Jason Kantor downgraded the rating on Cubist Pharmaceuticals Inc (NASDAQ: CBST) from Outperform to Neutral, but reiterated the $77.00 price target. In the report, Credit Suisse noted, “CBST has executed nearly flawlessly in building its US...

XOMA Corp (NASDAQ: XOMA) experienced volatility Monday after Ladenburg Thalmann downgraded the stock to Neutral and removed its price target while Wedbush reiterated its Outperform rating and $14 price target. Wedbush analyst Liana Moussatos noted that the “company ended Q3 with $59....

In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated a Neutral rating and $8.00 price target on Ariad Pharmaceuticals (NASDAQ: ARIA). In the report, Credit Suisse noted, “Iclusig sales increased modestly in the US and EU over last quarter. However, we expect that future US...

In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating on Esperion Therapeutics Inc (NASDAQ: ESPR), and raised the price target from $26.00 to $38.00. In the report, Credit Suisse noted, “Study 008 clearly demonstrated the superior efficacy of ETC-1002...

In a report published Friday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating and $34.00 price target on Kite Pharma (NASDAQ: KITE). In the report, Credit Suisse noted, “KITE continues to make progress toward an IND filing in 2014 and initiation of a pivotal study in H1:15. The...

In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating on BIND Therapeutics (NASDAQ: BIND), but lowered the price target from $21.00 to $20.00. In the report, Credit Suisse noted, “BIND announced that AMGN declined to exercise its option for BIND's...

In a report published Monday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating and $121.00 price target on Pharmacyclics (NASDAQ: PCYC). In the report, Credit Suisse noted, “We are raising our Q2 US Imbruvica sales forecast to $94M from $80M, based on recent IMS prescription and...